Development of a Robust UPLC Method for Simultaneous Determination of a Novel Combination of Sofosbuvir and Daclatasvir in Human Plasma: Clinical Application to Therapeutic Drug Monitoring
Table 2
(a) Accuracy, intraday, and interday precision and % extraction recovery for SF and DC in their QC samples in human plasma (n=6)
Nominal Concentration (ng.mL−1)
SF
Average of the measured concentration (ng.ml−1)
Accuracy (% Bias)
Intra-day precision (% CV)
Inter-day precision (% CV)
% Extraction recovery ± %CV
25
24
-4.0
9.6
8.6
96.0 ± 1.2
50
45
-10.0
4.6
5.1
90.0 ± 3.5
400
425
6.3
5.2
9.3
106.3 ± 1.3
3200
3430
7.2
3.9
7.4
107.2 ± 2.8
6400
6123
-4.3
3.8
6.1
95.7 ± 1.5
Nominal Concentration (ng.mL−1)
DC
Average of the measured concentration (ng.ml−1)
Accuracy
Intra-day precision
Inter-day precision
% Extraction recovery ± %CV
50
54
8.0
6.5
3.7
108.0 ± 2.3
100
95
-5.0
9.2
9.1
95.0 ± 1.7
1600
1490
-6.9
4.7
7.5
93.1 ± 1.1
6400
6690
4.5
5.4
6.4
104.5 ± 2.0
12800
12357
-3.5
2.8
8.2
96.5 ± 3.6
(b) Accuracy, intraday, and interday precision and % extraction recovery for SF and DC in their QC samples in human plasma (n=6)
